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The premenstrual phase of the menstrual cycle is associated with marked changes in normal and abnormal motivated behaviors.
Animal studies suggest that such effects may result from actions of gonadal hormones on the mesolimbic dopamine (DA) system.
We therefore investigated premenstrual changes in reward-related neural activity in terminal regions of the DA system in humans.
Twenty-eight healthy young women underwent functional magnetic resonance imaging on 2 days during the menstrual cycle,
once during the late follicular phase and once during the premenstrual phase, in counterbalanced order. Using a modified version
of the monetary incentive delay task, we assessed responsiveness of the ventral striatum to reward anticipation. Our results show
enhanced ventral striatal responses during the premenstrual as compared to the follicular phase. Moreover, this effect was most
pronounced in women reporting more premenstrual symptoms. These findings provide support for the notion that changes in
functioning of mesolimbic incentive processing circuits may underlie premenstrual changes in motivated behaviors. Notably,
increases in reward-cue responsiveness have previously been associated with DA withdrawal states. Our findings therefore
suggest that the sharp decline of gonadal hormone levels in the premenstrual phase may trigger a similar withdrawal-like state.
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INTRODUCTION
The premenstrual phase of the menstrual cycle, when pro-
gesterone and estradiol levels decline after a relatively stable
period with high levels, is associated with marked changes in
normal and abnormal motivated behaviors. For example,
increases have been shown of food cravings (Tomelleri and
Grunewald, 1987; Dye et al., 1995) and excessive cleaning
(Dillon and Brooks, 1992) in healthy women during the
premenstrual phase. Such symptoms are aggravated in
women with premenstrual syndrome (PMS) and premen-
strual dysphoric disorder (PMDD) (York et al., 1989; Reed
et al., 2008). Moreover, women with obsessive compulsive
disorder (OCD) and nicotine and cocaine abusers show an
exacerbation of compulsive and craving symptoms, respect-
ively, in the premenstrual phase (Allen et al., 2000; Evans
et al., 2002; Franklin et al., 2004; Vulink et al., 2006). Because
such motivated behaviors are associated with dopaminergic
(DA) functioning, these behavioral changes are thought to
arise from effects of gonadal hormone fluctuations on the
mesolimbic DA system (Chen et al., 1996; Thompson and
Moss, 1997; Reddy and Kulkarni, 1998, 1999). Previous
human neuroimaging studies have shown menstrual cycle
dependent (Ferna ´ndez et al., 2003; Goldstein et al., 2005;
Protopopescu et al., 2005; Dreher et al., 2007; Weis et al.,
2008) and exogenous gonadal hormone related changes in
brain function (Hermans et al., 2008; van Wingen et al., 2008
and 2009; Hermans et al., 2010). However, neural mechan-
isms in the premenstrual phase potentially underlying the
change in motivated behaviors during this phase have
never been investigated in humans.
A substantial body of animal research has shown that go-
nadal hormones exert actions on the mesolimbic DA system
(Kuppers et al., 2000; Mani, 2006). Estrogen and progesteron
receptors are expressed in the nucleus accumbens (NAcc),
a terminal region of the mesolimbic DA system (Roy et al.,
1986; Shughrue et al., 1998; McEwen, 2002; Mani, 2008).
Both progesterone and estrogens have been shown to in-
crease DA turnover in this region (Di Paolo et al., 1985;
Bazzett and Becker, 1994; Di Paolo, 1994; Thompson and
Moss, 1994; Petitclerc et al., 1995; Le Saux et al., 2006;
Larson and Carroll, 2007). The striatum moreover exhibits
high accumulations of neuroactive metabolites of progester-
one such as allopregnanolone, which are allosteric modula-
tors of the g-aminobutyric acid type A (GABA-A) receptor
(Bixo et al., 1986; Wang et al., 1995). The decline in gonadal
hormone levels in the premenstrual phase may therefore
explain alterations in DA-related motivated behaviors. In
support of this notion, animal studies have found that
experimentally induced hormone fluctuations can result in
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such as compulsions (Flaisher-Grinberg et al., 2009).
Human studies using blood oxygenation level dependent
functional magnetic resonance imaging (BOLD-fMRI) have
repeatedly demonstrated reward-related neural activity in a
set of regions that are innervated by DA projections from the
mesolimbic pathway (Knutson and Cooper, 2005; McBride
et al., 2006). BOLD responses in the ventral striatum (the
approximate location of the NAcc) have been shown to be
particularly strong during reward anticipation (Knutson
et al., 2001a and b), and when instrumental responses are
required to attain rewards (Bjork and Hommer, 2007).
Moreover, responses in this region to food-related stimuli
have been shown to be increased when participants are in a
state of hunger (LaBar et al., 2001). Increased ventral striatal
BOLD responses to drug-related cues have been associated
with craving and drug withdrawal (Kilts et al., 2001, 2004;
Rolls and McCabe, 2007; Wrase et al., 2007), although
opposite effects have also been observed for non-drug related
reward cues (Wrase et al., 2007; van Hell et al., 2010). Based
on behavioral findings described above, we expected to find
a more generally increased reward sensitivity in women in
the premenstrual phase, and therefore predicted that ventral
striatal activation during anticipation of monetary rewards
would be enhanced in the premenstrual phase. In addition,
we explored whether cycle-dependent changes in ventral stri-
atal activity would be associated with inter-individual differ-
ences in neuroactive steroid fluctuations and self-report
measures of premenstrual symptoms.
To address these questions, 28 healthy women underwent
fMRI once in the premenstrual phase and once in the late
follicular phase of the menstrual cycle in a counterbalanced
crossover design. Women were scanned in these particular
menstrual cycle phases because PMS and PMDD patients are
most symptomatic in the premenstrual phase and are least
symptomatic in the late follicular phase (Sveindottir and
Ba ¨ckstro ¨m, 2000). In the MRI scanner, participants per-
formed a modified version of the monetary incentive delay
(MID) task (Knutson et al., 2001a) in which cues were
presented that either signaled trials that were potentially
rewarding or non-rewarding. Interindividual differences in
premenstrual symptoms were assessed using the Moos
Menstrual Distress Questionnaire (MDQ; Moos, 1968).
Additionally, we collected saliva for measuring neuroactive
steroid levels (allopregnanolone). For menstrual cycle phase
verification, we used ovulation predictor kits and obtained




Twenty-eight healthy right-handed women (mean age:
22.8 years, range: 18–38 years) participated in this study.
None of the women had used hormonal contraceptives for
the previous 3 months and all had regular menstrual cycles
(26–32 days over the past year). Women were excluded when
they consumed more than three alcoholic beverages per day
on average and smoked more than 20 cigarettes per week. In
addition, they were asked not to consume alcohol 24h prior
to the experiment or to use psychoactive substances for 72h.
They had no history of psychiatric disorders (as determined
with the Mini International Neuropsychiatric Interview,
M.I.N.I) (Sheehan et al., 1998) and were additionally
screened specifically for PMDD or PMS using the Dutch
version of the MDQ (Moos, 1968). All women were physic-
ally healthy and reported no MRI contraindications. Data of
one woman were excluded from data analysis due to exces-
sive head movement during scanning. The study was
approved by the local ethical review board (CMO Region
Arnhem-Nijmegen, The Netherlands) and all women pro-
vided written informed consent.
Design and procedure
Women were tested in a crossover design with the counter-
balanced factors menstrual cycle phase (late follicular vs pre-
menstrual) and condition (potentially rewarding vs
non-rewarding) as within subject factors. During a screening
day prior to scanning sessions, subjects completed the MINI
(Sheehan et al., 1998) and the MDQ (Moos, 1968). Each
woman was scanned in the afternoon or evening once
during the late follicular phase and once during the premen-
strual phase. Time of day was kept equal for both test ses-
sions (within participants). Timing of test sessions within the
menstrual cycle phase was ascertained as follows. For the late
follicular phase, test sessions were planned between Days 8
and 12 (mean time point of test session: Day 10, s.d.: 1day)
with respect to the first day of the menstrual cycle (i.e. start
of menstruation). To determine the premenstrual phase, two
time points were used. First, participants contacted the ex-
perimenter when they had a positive result from their
LH-peak assessments (as determined using commercially
available ovulation predictor kits; Wondfo Biotech,
Guangzhou, China). Subsequently, an appointment was
made for premenstrual scanning  14 days after the start of
ovulation. To ascertain that this test session took place in the
premenstrual phase, participants were asked to contact the
experimenter again when their next menstruation started
(mean time point of test session: 2 days before menstruation
started, s.d.: 1day). Menstrual cycle phases could further be
verified retrospectively using salivary neuroactive steroid
concentrations (see below).
On testing days, participants arrived between 2 and 7pm.
Approximately 1.5h before scanning, subjects practiced the
MID task outside the scanner. In order to measure salivary
concentrations of allopregnanolone, 10ml of saliva was col-
lected at the beginning of each test session (5min after ar-
rival). Saliva was collected in plastic tubes and kept frozen at
 208C. Participants lay in the scanner in a supine position.
During and between preparation scans, participants per-
formed a training run of the MID.
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This task was based on the MID task developed by Knutson
et al. (2001) and consisted of 25 potentially rewarding trials,
25 non-rewarding trials and 25 periods of low-level fixation
with a mean duration equal to trials. In total, trials lasted
between 8.5 and 11.5s (mean 10s). Thus, the total duration
of the task was 12.5min. At the beginning of each trial, a cue
(cue duration: 3.5–8.5s; mean: 6s) was presented signaling a
potentially rewarding (red square) or non-rewarding (green
square) trial. Following this cue, a target was presented to
which subjects had to respond as fast as possible (by pressing
a button) irrespective of the cue type. When the button was
pushed within the presentation time of the circle, the target
remained on the screen, thus providing the participant with
feedback that the target was hit. Otherwise, it disappeared.
When the target was hit in a rewarding trial, they earned one
euro. After disappearance of the target (duration: 1.2–5.3s;
mean 3.25s), short feedback was provided (500ms) of the
current cumulative gain. To ascertain that reward outcome
was similar across participants and sessions, the target dur-
ation was variable (150–500ms) and shortened with 20ms
for the subsequent trial when the previous target was hit. The
target duration was lengthened with 10ms in the subsequent
trial when the previous target was missed. This procedure
results in a hit rate of  33% on average, ensuring that all
participants won approximately the same amount of money
(between 8 and 11 euros). Prior to the experiment, practice
trials were presented outside and inside the scanner to
familiarize the participants with the task. They were required
to hit the target in five and three potentially rewarding trials,
respectively, before procedures continued. This task was per-
formed twice, once during the late follicular phase and once
during the premenstrual phase.
MR data acquisition
MRI scans were collected using a Siemens (Erlangen,
Germany) TIM Trio 3.0T MRI scanner equipped with an
eight channel phased array head coil. The following scans
were obtained:two runs of 402 T2* weighted BOLD
images each (gradient echo EPI, TE/TR: 25/1890ms, flip
angle 808, FOV: 212 212mm, matrix 64 64, 3-mm slice
thickness, 0.3mm slice gap, 37 ascending slices. To reduce
signal drop-out and geometric distortions, we used a short
TE, an oblique axial angulation (de Zwart, 2006), and
reduced echo-train length by means of factor 2 accelerated
GRAPPA (Griswold et al., 2002). Structural scans were ob-
tained using an MP-RAGE sequence (TE/TR: 2.96/2300ms,
flip angle: 88, FOV: 256 256 192mm, voxel size: 1mm
isotropic, GRAPPA acceleration factor 2).
Analysis of behavioral performance
For each participant, reaction time (RT) data of responses to
targets during the modified MID task were filtered by
removing values outside the 150–1000ms range. In addition,
those RTs exceeding 3s.d’s from the mean were removed.
Furthermore, one participant, who had mean RTs>3s.d.
from the group average, was excluded from further RT ana-
lyses. RTs were analysed using a repeated measures ANOVA
with menstrual cycle phase and reward condition as
within-subject factors. Alpha was set at 0.05. As a result of
the adaptive procedure adjusting the target presentation time
(see above), the total amount of monetary gain in the MID
task does not reflect performance.
Analysis of fMRI data
fMRI data were analysed using Statistical Parametric
Mapping software (SPM5; Wellcome Department of
Imaging Neuroscience, London). To allow for T1 equilibra-
tion, the first five EPI-volumes of each run were discarded.
The remaining images were realigned to the first volume,
slice time corrected, coregistered to the structural MR
image, spatially normalized to standard Montreal
Neurological Institute (MNI) 152 coordinate space,
resampled into 2 2 2mm
3 voxels, and smoothed with
an isotropic 8-mm full-width half maximum Gaussian
kernel.
Statistical analysis was performed within the framework of
the general linear model. For each of the two runs, the re-
warding and non-rewarding trials were modeled as separate
regressors in an event-related manner for the duration of the
anticipation cue (i.e. between 3.5 and 8.5s for both the red
and the green square). Subsequently, these regressors were
convolved with the canonical hemodynamic response func-
tion implemented in SPM5. The six parameters correspond-
ing with head movement obtained from the realignment
procedure were also included in the model for both sessions,
as well as a high-pass filter with a 1/128Hz cut-off frequency.
We applied proportional global signal scaling to reduce ef-
fects due to global signal variations between scan sessions.
The single subject parameter estimates of each session and
condition obtained from the first level analysis were included
into subsequent second level analyses treating subjects as
random variables. A repeated measures ANOVA was used,
with menstrual cycle phase (late follicular vs late premen-
strual) and reward condition (potentially rewarding vs
non-rewarding) as within-subject factors, with non-
sphericity corrections for repeated measures. For our main
region of interest (NAcc), a small volume correction (SVC)
was used that was based on an anatomical mask of this
region. This mask was created as follows: bilateral NAcc
was delineated in T1 weighted scans of 60 separate individ-
uals (21 males, 39 females; mean age: 21.9 years, age range:
18–38 years) using an automated segmentation procedure as
implemented in FSL FIRST (see http://www.fmrib.ox.ac
.uk/fsl/first/index.html). Subsequently, all T1-weighted
images were normalized into MNI152 space using SPM5 as
described earlier, and the same transformation was applied
to all segmented images. After visual inspection, all seg-
mented images (boolean maps) were averaged, resulting in
a probability mask. This mask was thresholded at a
614 SCAN (2011) L.Ossewaardeetal.probability of 0.75 (total volume: 2179mm
3). Given the
uncertainties in exact localization of a small area such as
the NAcc, we refer to the region covered by this ROI mask
with the more cautious term ventral striatum. A FWE cor-
rection for multiple comparisons across the entire brain was
used for all other brain regions.
For additional correlation analyses with allopregnanolone
changes across the menstrual cycle and MDQ scores, con-
trast estimates reflecting the premenstrual increase in
reward-related responses were extracted from the largest
ventral striatal cluster (consisting of 16 voxels in the left
ventral striatum) in the interaction effect (peak voxel at
 6, 20,  4; ‘Results’ section). The MDQ consists of eight
different subscales (pain, water resistance, autonomic reac-
tions, negative affect, impaired concentration, behavioral
changes, arousal and control), and for every subscale a
score for three cycle phases (during menstruation, premen-
strual and rest of the cycle) was obtained. For every subscale,
we calculated a difference score reflecting premenstrual
symptoms (premenstrual vs rest of the cycle).
Subsequently, by taking the sum across all subscales, a
total MDQ difference score was calculated, which was used
for the correlational analysis. A similar analysis was per-
formed with the difference in allopregnanolone levels be-
tween the late follicular and the premenstrual phase.
Gonadal steroid analysis
Saliva samples were collected to assess levels of neuroactive
steroids (allopregnanolone). The sampling procedure and
assay of salivary allopregnanolone has been detailed previ-
ously (Ossewaarde et al., 2010). The samples were
thawed and allopregnanolone extracted with diethyl ether.
A separation of cross reacting steroids was made with high
performance liquid chromatography and thereafter a radio-
immunoassay (RIA) was made using an allopregnanolone
antiserum kindly provided by Dr R.H. Purdy, Department
of Physiology and Pharmacology, the Scripps Research
Institute, La Jolla, CA, USA (Purdy et al., 1990) and
[11,12]
3H-allopregnanolone (Perkin Elmer Life Sciences,
Boston, USA). The sensitivity of the assay was 19pg. The
recovery of allopregnanolone was calculated by using
spiked saliva samples and was mean 76.2% range
(62–92%) and the results are compensated for recovery.
The intraassay coefficient of variation was 21% in these
saliva samples. Due to the experimental nature and novelty
of the allopregnanolone assessment based on saliva, the
entire samples were used for this analysis. Note, however,
that progesterone and allopregnanolone levels are strongly
positively correlated with each (Wang et al., 1996).
RESULTS
Allopregnanolone assessment
The saliva concentrations of allopregnanolone were higher in
the premenstrual phase (mean s.d., 0.050nmol/l 0.016)
than the late follicular phase (mean s.d., 0.035nmol/
l 0.010) (t25¼4.67, P<0.001). Kolmogorov–Smirnov
tests confirmed that the distributions of allopregnanolone
concentrations in the two cycle phases did not deviate
from a normal distribution (both Z<1). Moreover, distri-
butions contained no outliers. Note that levels of allopreg-
nanolone are tightly linked to levels of progesterone (Wang
et al., 1996). Although estradiol and/or progesterone levels
are more commonly used for confirmation of menstrual
cycle phase, these data therefore do indicate that participants
were tested during the intended menstrual cycle phase.
MID Task, RTs
A repeated-measures ANOVA with reward condition (po-
tentially rewarding vs non-rewarding) and menstrual cycle
phase (late follicular vs premenstrual) as within subject fac-
tors revealed a main effect of reward condition
[F(1,25)¼61.50, P<0.001], indicating that responses to
the target during potentially rewarding trials were faster
than to non-rewarding trials (mean s.d. in ms, premen-
strual phase: potentially rewarding 227 20; non-rewarding
261 30, late follicular phase: reward 228 21; non-reward
259 27). There was neither a main effect of menstrual cycle
phase [F(1,25)¼0.56, ns], nor an interaction between men-
strual cycle phase and reward condition [F(1,25)¼0.21, ns].
The adaptive reinforcement schedule indeed resulted in a
rewarding outcome in  33% of potentially rewarding
trials: observed mean percentages of hits (and s.d.) were
39.2% (4.9%) and 35.9% (6.4%) for potentially rewarding
and non-rewarding conditions, respectively.
Functional MRI results
fMRI data were analysed with a second-level repeated meas-
ures ANOVA with reward condition (potentially rewarding
vs non-rewarding) and menstrual cycle phase (late follicular
vs premenstrual) as within subject factors, using SVCs for
our main region of interest: the ventral striatum (‘Materials
and methods’ section). The main effect of reward condition
showed expected activations in ventral and dorsal striatum,
midbrain, parietal regions, insula and anterior cingulate
gyrus, confirming previous observations (Knutson et al.,
2001a, b) (Table 1). Next, we investigated whether reward
condition effects differed between the two menstrual cycle
phases. A significant interaction between reward condition
and menstrual cycle phase was observed in the ventral stri-
atum (P¼0.015, SVC), with larger reward condition effects
in the premenstrual phase (Figure 1A, Table 1). Separate
tests for the premenstrual and late follicular phases nonethe-
less showed robust reward condition effects in the ventral
striatum in both menstrual cycle phases (both P<0.001,
SVC; Figure 1B and C, Table 1). No main effects were
found of the factor menstrual cycle phase in the ventral stri-
atum (P>0.05, SVC) or other reward-related brain areas
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hypothesis of enhanced ventral striatal reward-related activ-
ity in the premenstrual phase.
Additionally, we investigated the relationship between
menstrual cycle related changes in ventral striatal activity
and individual differences in the sensitivity to gonadal hor-
mone changes as reflected by allopregnanolone changes and
the total MDQ difference score (displaying premenstrual
symptoms as compared to symptoms during the rest of the
cycle). Reward-related activation (potentially rewarding vs
non-rewarding activity) in the ventral striatum during the
late follicular phase was subtracted from activation during
the premenstrual phase, yielding an estimate of the inter-
action effect described earlier. Although there was no signifi-
cant correlation with menstrual cycle related changes in
allopregnanolone levels (P>0.05), results showed a positive
correlation between the interaction effect and total MDQ
difference scores [r(27)¼0.46, P<0.05]. This indicates
that women with the highest total MDQ difference scores
had the largest premenstrual increase in ventral striatal ac-
tivity. When exploring the different subscales, negative affect
[r(27)¼0.42, P<0.05], behavioral changes [r(27)¼0.45,
P<0.05] and control [r(27)¼0.54, P<0.01] showed a sig-
nificant positive association with the menstrual cycle related
Table 1 Local maxima for significant areas of activation for the main and simple effects, and menstrual cycle phase reward interaction
Side xyzT -value
Main effect of reward condition: reward>non-reward
Ventral striatum R 8 8  4 7.64**
Ventral striatum L  86  4 9.01**
Supplementary motor area R/L 4 6 54 9.35***
Cerebellum L  38  54  30 8.87***
Cerebellum R 30  58  26 6.95***
Insula R 46 20  8 6.92***
Insula L  32 28 0 6.76***
Primary motor cortex R 52  2 50 5.58***
Primary motor cortex L  46  6 58 5.87***
Parahippocampal gyrus R 14  24  12 5.67***
Midbrain R/L 0  18  18 5.54***
Mid-cingulate gyrus R 16  28 44 5.44***
Hippocampus L  22  24  10 5.00***
Middle frontal gyrus R 34 42 26 5.13***
Middle frontal gyrus L  34 46 24 4.95***
Menstrual cycle phase reward interaction: premenstrual>late follicular
Ventral striatum R 8 20  2 3.54*
Ventral striatum L  82 2  2 3.48*
Premenstrual reward>premenstrual non-reward
Ventral striatum R 10 14  6 6.97**
Ventral striatum L  88  4 7.46**
Supplementary motor area R/L 4 8 50 7.51***
Cerebellum L  38  54  30 7.76***
Thalamus L  6  4 6 8.02***
Hippocampus R 16 4  14 5.43***
Hippocampus L  16  6  10 5.47***
Insula R 46 20  6 6.07***
Insula L  32 28  2 5.79***
Middle frontal gyrus R 34 40 26 5.01***
Mid-cingulate gyrus R 16  30 46 4.97***
Follicular reward>follicular non-reward
Ventral striatum R 8 8  4 5.94**
Ventral striatum L  10 6  6 7.28**
Supplementary motor area R/L 4 6 54 7.63***
Cerebellum R 32  56  28 5.16***
Cerebellum L  36  52  32 7.20***
Insula R 32 24  8 6.13***
Insula L 46 20  6 6.07***
Midbrain R/L 2  18  18 5.75***
Parahippocampal gyrus R 12  22  14 5.46***
Temporal pole R 60 10 2 5.01***
*P<0.05, FWE rate corrected for the reduced search volume (ventral striatum).
**P<0.001, FWE rate corrected for the reduced search volume (ventral striatum).
***P<0.05, FWE rate corrected for the entire brain.
R, right; L, left.
616 SCAN (2011) L.Ossewaardeetal.change in ventral striatal reward activity. The subscales pain,
water resistance, autonomic reactions and arousal did not
reach the statistical threshold (all P>0.05).
DISCUSSION
The aim of the present study was to identify potential neural
mechanisms underlying changes in motivated behaviors
across the menstrual cycle. As hypothesized, we observed
premenstrual increases in reward-related BOLD responses
in the ventral striatum, a target region of the mesolimbic
DA system. Notably, this premenstrual increase in ventral
striatal activity was most pronounced in women who re-
ported more premenstrual symptoms. Together, these find-
ings support the notion that dysregulations of dopaminergic
incentive processing circuits underlie premenstrual symp-
toms related to changes in motivated behaviors.
The observed increase of reward-related responses in the
ventral striatum during the premenstrual phase can be ex-
plained by two possible neurobiological mechanisms. First,
the observed findings may be caused by a delayed effect of
changes in absolute levels of gonadal hormones across the
menstrual cycle. In line with this notion, serum progesterone
concentrations robustly predict negative symptom severity in
women with PMS with a delay of  3–4 days (Wang et al.,
1996). These patients moreover exhibit recurrent food crav-
ings which are related to the steroid and mood state fluctu-
ations across the menstrual cycle (Dye et al., 1995; Dye and
Blundell, 1997). Furthermore, it has been shown that espe-
cially hedonic intake of palatable food is increased by





















Fig. 1 Statistical brain activation T-maps showing menstrual cycle phase by reward interaction, and simple effects. (A) Menstrual cycle phase by reward interaction (P<0.001,
uncorrected, for visualization purposes). (B) Reward activity during the late follicular phase (P<0.05, whole brain FWE corrected). (C) Reward activity during the premenstrual
phase (P<0.05, whole brain FWE corrected). R, right side of the brain; L, left side of the brain; FWE, family wise error.
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on reward seeking (Chen et al., 1996; Reddy and Kulkarni,
1998, 1999). Second, premenstrual increases in ventral stri-
atal responsiveness may be caused by the ‘decline’ of gonadal
hormone levels during the premenstrual phase. Because go-
nadal hormones are known to potentiate DA release
(Di Paolo et al., 1985; Bazzett and Becker, 1994; Di Paolo,
1994; Thompson and Moss, 1994; Petitclerc et al., 1995; Le
Saux et al., 2006; Larson and Carroll, 2007), their decline in
the premenstrual phase after a period of increased levels may
prompt a down-regulation of endogenous DA activity and
thus mimic a withdrawal state.
Previous studies have shown that dopaminergic with-
drawal states are associated with enhanced cue-induced
DA release, which is thought to attribute ‘incentive salience’,
or motivational value, to drug or reward associated
stimuli (Robinson and Berridge, 1993). Notably, in
humans, such withdrawal states appear to prompt changes
in motivated behavior and its neural substrates that are
analogous to the findings reported here, with enhanced
ventral striatal responsiveness to food or drug cues
(Kilts et al., 2001; Rolls and McCabe, 2007). Therefore,
increased ventral striatal responsiveness in the premenstrual
phase may result from a similar DA withdrawal state that is
caused by the abrupt decline in gonadal hormone levels. To
corroborate this notion, future research in humans should
investigate whether the present findings generalize to other
periods of gonadal hormone decline, such as postpartum or
(peri) menopausal periods. Furthermore, effects of con-
trolled hormone withdrawal can be investigated either
through termination of hormone replacement therapy or
hormonal contraception, or through pharmacological go-
nadal suppression using administration of gonadotropin-
releasing hormone agonists such as leuprolide. Such
studies may shed new light on potential gonadal hor-
mone withdrawal effects both on neuronal and behavioral
levels.
An important limitation of the present study is that the
BOLD-fMRI signal in the ventral striatum cannot provide
direct information about dopaminergic neurotransmission.
However, a recent fMRI study has shown that BOLD re-
sponses during reward anticipation in the ventral striatum
correlate positively with DA release (Schott et al., 2008). It
has been suggested that the ventral striatal BOLD signal re-
flects changes in postsynaptic D1-receptor agonism
(Knutson and Gibbs, 2007). Pharmacological fMRI studies
have indeed shown that DA agonists induce ventral striatal
BOLD responses (Breiter et al., 1997; Vollm et al., 2004).
Although this suggests that the ventral striatal BOLD signal
is related to DA function, our findings do not necessarily
represent elevated DA release specifically. Moreover, conclu-
sions regarding the specificity of our finding to reward an-
ticipation are limited by the fact that our task only included
trials with anticipated rewards and non-rewarding control
trials.
In conclusion, the present study demonstrated enhanced
reward-related neural responses in the ventral striatum
during the premenstrual phase. These findings provide sup-
port for the notion that changes in functioning of mesolim-
bic incentive processing circuits may underlie premenstrual
increases in normal and abnormal motivated behaviors such
as food and drug cravings. These effects are likely caused by
the sudden decrease in gonadal hormone levels during the
premenstrual phase and may thus reflect a withdrawal-like
state. The results of the present study may generalize to other
periods of instability in the gonadal hormone milieu and
may therefore provide novel insights into the pathophysi-
ology of psychiatric disorders associated with gonadal hor-
monal fluctuations.
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